Nonprofit researcher SRI International has struck a deal with Japanese drugmaker Nobelpharma to collaborate on a new treatment for the painful gynecological disease endometriosis.
AliveCor, the maker of the first FDA-approved smartphone-based device to detect atrial fibrillation, is partnering with Apollo Hospitals to provide the monitor to patients throughout India.
The Defense Advanced Research Projects Agency awarded Harvard University engineers up to $2.9 billion to develop a robotic suit to make walking easier for soldiers and potentially civilians with disabilities, the university announced today.
Blackberry is launching an ambitious project to integrate thousands of medical devices in India in order to detect illnesses earlier.
Genmab is taking its cancer drug collaboration with Seattle Genetics one more step forward. The Danish biotech is handing over an $11 million upfront and promising up to $200 million more to get the right to use Seattle Genetics' antibody-drug conjugate technology for its HuMax-AXL program.
Ophthotech says it won a $50 million enrollment milestone from Novartis for reaching a goal on its Phase III Fovista study for wet, age-related macular degeneration.
Facing dwindling sales and a thin late-stage pipeline, Merck KGaA is looking to accelerate its efforts in allergy drug development, signing a deal with an Austrian biotech with hopes of quickly seeding new programs in the field.
The deadly outbreak of Ebola in West Africa is pushing related vaccine and drug development efforts from first gear into overdrive. Today it's J&J's turn to step up, teaming with the Danish biotech Bavarian Nordic to pair up vaccine components into a new jab with the help of the National Institute of Allergy and Infectious Diseases. And the pharma giant says it can start testing the new combination vaccine in a rushed clinical trial slated to start in early 2015.
Hot on the heels of its $805 million development deal with Infinity, AbbVie Pharmaceuticals has followed up today with a plan to partner with Google's closely watched biotech upstart Calico on a new research operation that will cost up to $1.5 billion to get started.
BioTime is entering into a partnership with the University of Wisconsin and Belgium's Louvain University to develop the company's hydrogel-based treatment for vocal fold scarring.